Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts

European Journal of Cancer

Volumn 35, Issue 3, 1999, Pages 512-520

  Hill, B T ^a   Fiebig, H H ^b   Waud, W R ^c   Poupon, M F ^d   Colpaert, F ^a   Kruczynski, A ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b UNIVERSITY OF FREIBURG   (Germany)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d CNRS   (France)

Author keywords

Cancer chemotherapy; Human tumours; Vinflunine; Vinorelbine; Xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; NAVELBINE; UNCLASSIFIED DRUG; VINCA ALKALOID; VINFLUNINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; VINBLASTINE;

EID: 0033105721     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00416-X     Document Type: Article

References (22)

1. Fahy J., Duflos A., Ribet J.-P., et al. Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. JACS. 36:1997;8576-8577.
2. Kruczynski A., Colpaert F., Tarayre J.-P., Mouillard P., Fahy J., Hill B.T. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother. Pharmacol. 41:1998;437-447.
3. Kruczynski A., Colpaert F., Tarayre J.-P., Mouillard P., Fahy J., Hill B.T. In vivo antitumour activity of F12158, a novel fluorinated Vinca alkaloid. Proc. Am. Assoc. Cancer Res. 38:1997;224-225.
4. Kruczynski A., Barret J.-M., Etievant C., Colpaert F., Fahy J., Hill B.T. Antimitotic and tubulin interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem. Pharmacol. 55:1998;635-648.
5. Etievant C, Barret J-M, Kruczynski A, Perrin D, Hill BT. Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs 1998, 16, 3-17.
6. Lobert S, Ingram JW, Hill BT, Correia JJ. A comparison of thermodynamic parameters for vinroelbine- and vinflunine-induced tubulin self association by sedimentation velocity. Mol Pharmacol 1998, 53, 908-915.
7. Berger DP, Winterhalter BR, Fiebig HH. Establishment and characterization of human tumor xenografts in thymus aplastic nude mice. In Fiebig HH, Berger DP, eds. Immunodeficient Mice in Oncology. Contrib Oncol Basel, Karger, 1992, 23-46.
8. Fiebig HH, Berger DP, Dengler WA, Wallbrecher E, Winterhalter BR. Combined in vitro/in vivo test procedure with human tumor xenografts. In Fiebig HH, Berger DP, eds. Immunodeficient Mice in Oncology. Contrib Oncol Basel, Karger, 1992, 321-351.
9. Remvikos Y., Vogt N., Muleris M.M., et al. DNA-repeat instability is associated with colorectal cancers presenting minimal chromosome rearrangements. Genes, Chromosomes & Cancer. 12:1995;272-276.
10. Dexter D.J., Barbosa J.A., Calabresi P. N,N-dimethyl formamide-induced alterations of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res. 39:1979;1020-1025.
11. Fogh J, Trempe G. In Fogh J, ed. Human Tumor Cells In Vitro. New York, Plenum Press, 1975, 115-159.
12. Rutka J.T., Giblin J.R., Dougherty D.Y., et al. Establishment and characterization of five cell lines derived from human malignant gliomas. Acta Neuropathol. 75:1987;92-103.
13. Gazdar A.F., Carney D.N., Russell E.K., et al. Establishment of continuous, clonable cultures of small-cell carcinoma of the lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res. 40:1980;3502-3507.
14. Kaighn M.E., Narayan K.S., Ohnuki Y., et al. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 17:1979;16-23.
15. Hendriks H.R., Langdon S., Dietmar P.B., et al. Comparative antitumour activity of vinblastine-isoleucinate and related Vinca alkaloids in human tumour xenografts. Eur. J. Cancer. 28A:1992;767-773.
16. Bissery M.C., Guenard D., Gueritte-Voegelein F., Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 51:1991;4845-4852.
17. Bissery M.C., Vrignaud P., Lavelle F., Chabot G.G. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anti-Cancer Drugs. 7:1996;437-460.
18. Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC. Human tumor xenograft models in NCI drug development. In Teicher B, ed. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval. Totowa, New Jersey, Humana Press, 1997, 101-125.
19. Fodstad O. Preclinical anticancer drug evaluation in human tumor xenografts. In Fiebig HH, Berger DP, eds. Immunodeficient Mice in Oncology. Contrib Oncol Karger, Basel, 1992, 353-361.
20. Winograd B., Boven E., Lobbegoo M.W., Pinedo H.M. Human tumor xenografts in the nude mouse and their value as test models in anti-cancer drug development. In Vivo. 1:1987;1-14.
21. Johnson IS, Amstrong JG, Gorman M, Burnett JP. Vinorelbine: an overview. Cancer Treat Rev 1996, 22, 127-142.
22. Blumenthal R.D., Sharkey R.M., Natale A.M., Kashi R., Wong G., Goldenberg D.M. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res. 54:1994;142-151.